Continuation of Clopidogrel in Total Knee Arthroplasty: Perioperative Bleeding and Cardiovascular Outcomes in a Consecutive Case Series
4 affiliations
- 1Joint Reconstruction Research Center, Tehran University of Medical Sciences, Tehran, Iran
- 2Joint Reconstruction Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Orthopedic Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
- 3Joint Reconstruction Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Orthopedic Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; Students’ Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran
- 4Joint Reconstruction Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Orthopedic Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; Corresponding author. Joint Reconstruction Research Center, Imam Khomeini Hospital Complex, Keshavarz Boulevard, Tehran 1419733141, Iran. Tel.: +9821-6658-1586.
Abstract
Background: Perioperative clopidogrel management in total knee arthroplasty (TKA) is challenging because interruption may increase thrombotic risk, whereas continuation may increase bleeding. Evidence remains limited. Methods: We retrospectively reviewed 31 consecutive patients (35 knees) undergoing primary TKA while continuing clopidogrel 75 mg daily (April 2018–September 2019). A multidisciplinary team involving orthopaedic surgery, cardiology, and anesthesiology determined continuation. One senior surgeon performed all procedures using a tourniquet-free technique with intravenous and intra-articular tranexamic acid. All patients also received low-dose aspirin for at least 2 weeks postoperatively as venous thromboembolism prophylaxis. Outcomes through 90 days included bleeding, transfusion, wound complications, infection, major adverse cardiac and cerebrovascular events, symptomatic venous thromboembolism, and anesthesia-related complications. Results: Mean age was 69 ± 6.4 years; mean estimated blood loss was 285 ± 95 mL, and mean hemoglobin decrease was 1.8 ± 0.6 g/dL. No transfusions or major bleeding occurred. Minor wound drainage followed 3 procedures (8.6%), and superficial cellulitis occurred in 1 knee (2.9%); no deep infections occurred. Four patients (12.9%) reported mild, nonspecific headaches; none met criteria for post-dural puncture headache. No clinical signs or symptoms suggestive of spinal hematoma or persistent neurologic deficit, and no myocardial infarction, stroke, or cardiovascular death, were observed. Conclusions: Clopidogrel continuation during primary TKA may be feasible in carefully selected patients receiving multidisciplinary assessment and multimodal blood management. The small sample, retrospective design, and absence of a control group preclude conclusions about comparative safety.
Related
- Patient-Perceived and Record-Based Concordance of AI-Generated Perioperative Information After Total Hip Arthroplasty: A Cross-Sectional Study with Multidisciplinary Review
- Response to "Interpreting Route, Dose, and Clinical Relevance in Perioperative Magnesium Sulfate After Total Knee Arthroplasty" [Response to Letter].
- vNOTES sentinel lymph node biopsy and hysterectomy for endometrial cancer staging: perioperative outcomes from a consecutive series
- Optimal strategy for treatment of atherosclerotic cardiovascular disease—comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study): a study protocol for a multicenter, open-label, randomized, non-inferiority trial
- Perioperative outcomes after aortic valve replacement via right anterior mini-thoracotomy with a rapid-deployment valve: a consecutive single-centre series
BibTeX
@article{ahmadabbaszadeh2026continuation,
title = {{Continuation of Clopidogrel in Total Knee Arthroplasty: Perioperative Bleeding and Cardiovascular Outcomes in a Consecutive Case Series}},
author = {Ahmad Abbaszadeh, MD and Seyed Mohammad Javad Mortazavi, MD and Mahdi Sahebi, MD, MPH and Mohammad Ayati Firoozabadi, MD},
journal = {Arthroplasty Today},
year = {2026},
month = nov,
doi = {10.1016/j.artd.2026.102204},
url = {https://doi.org/10.1016/j.artd.2026.102204},
note = {CC BY},
}
RIS
TY - JOUR
TI - Continuation of Clopidogrel in Total Knee Arthroplasty: Perioperative Bleeding and Cardiovascular Outcomes in a Consecutive Case Series
AU - Ahmad Abbaszadeh, MD
AU - Seyed Mohammad Javad Mortazavi, MD
AU - Mahdi Sahebi, MD, MPH
AU - Mohammad Ayati Firoozabadi, MD
PY - 2026
DA - 2026/11/11
JO - Arthroplasty Today
DO - 10.1016/j.artd.2026.102204
UR - https://doi.org/10.1016/j.artd.2026.102204
AB - Background: Perioperative clopidogrel management in total knee arthroplasty (TKA) is challenging because interruption may increase thrombotic risk, whereas continuation may increase bleeding. Evidence remains limited. Methods: We retrospectively reviewed 31 consecutive patients (35 knees) undergoing primary TKA while continuing clopidogrel 75 mg daily (April 2018–September 2019). A multidisciplinary team involving orthopaedic surgery, cardiology, and anesthesiology determined continuation. One senior surgeon performed all procedures using a tourniquet-free technique with intravenous and intra-articular tranexamic acid. All patients also received low-dose aspirin for at least 2 weeks postoperatively as venous thromboembolism prophylaxis. Outcomes through 90 days included bleeding, transfusion, wound complications, infection, major adverse cardiac and cerebrovascular events, symptomatic venous thromboembolism, and anesthesia-related complications. Results: Mean age was 69 ± 6.4 years; mean estimated blood loss was 285 ± 95 mL, and mean hemoglobin decrease was 1.8 ± 0.6 g/dL. No transfusions or major bleeding occurred. Minor wound drainage followed 3 procedures (8.6%), and superficial cellulitis occurred in 1 knee (2.9%); no deep infections occurred. Four patients (12.9%) reported mild, nonspecific headaches; none met criteria for post-dural puncture headache. No clinical signs or symptoms suggestive of spinal hematoma or persistent neurologic deficit, and no myocardial infarction, stroke, or cardiovascular death, were observed. Conclusions: Clopidogrel continuation during primary TKA may be feasible in carefully selected patients receiving multidisciplinary assessment and multimodal blood management. The small sample, retrospective design, and absence of a control group preclude conclusions about comparative safety.
SN - 2352-3441
ER -